Search Within

Sergio Andres Giralt

Formats
  1. Meeting Abstract (642)
  2. Journal Article (376)
  3. Research Letter (20)
  4. Review (15)
  5. Guidelines (5)
  6. Correspondence (4)
  7. Editorial (4)
  8. Book Section (3)
Groups
  1. Bone Marrow Transplant (1069)
  2. Center for Hematologic Malignancies (1069)
  3. Department of Medicine (1069)
  4. Hematologic Malignancies, Division of (1069)
  5. Survivorship Research (703)
  6. CTCR Scholars (557)

More Groups

People
  1. Miguel-Angel Perales (429)
  2. Sean Devlin (380)
  3. Gunjan Shah (311)
  4. Michael Scordo (279)
  5. Heather Landau (263)
  6. Ann Jakubowski (242)

More People

Years
  1. 2025 (18)
  2. 2024 (65)
  3. 2023 (104)
  4. 2022 (77)
  5. 2021 (66)
  6. 2020 (91)

More Years

Publications
  1. Blood (314)
  2. Biology of Blood and Marrow Transplantation (275)
  3. Bone Marrow Transplantation (80)
  4. Clinical Lymphoma, Myeloma and Leukemia (60)
  5. Journal of Clinical Oncology (40)
  6. Transplantation and Cellular Therapy (36)

More Publications

Publishers
  1. Elsevier Inc. (386)
  2. American Society of Hematology (349)
  3. Nature Publishing Group (110)
  4. American Society of Clinical Oncology (42)
  5. Taylor & Francis Group (35)
  6. Ferrata Storti Foundation (13)

More Publishers

Results (1069)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT)
    Meeting Abstract

    Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T.; Arnulf, B.; Cavo, M.; Nooka, A. K.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant
    Meeting Abstract

    Shah, G. L.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D. J.; Gupta, G. K.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma
    Research Letter

    Lin, R. J.; Kim, S. J.; Brown, S.; Elko, T. A.; Ruiz, J. D.; Hanley, D. M.; Palomba, M. L.; Perales, M. A.; Shah, G. L.; Dahi, P. B.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy
    Research Letter

    Mohan, M.; Janz, S.; Brazauskas, R.; Dwinell, M. B.; Teng, B. Q.; Yun, G.; Dong, J.; Pasquini, M. C.; Giralt, S.; Landau, H.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse
    Journal Article

    DeWolf, S.; Elhanati, Y.; Nichols, K.; Waters, N. R.; Nguyen, C. L.; Slingerland, J. B.; Rodriguez, N.; Lyudovyk, O.; Giardina, P. A.; Kousa, A. I.; more...
    Science Translational Medicine (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T‐cell therapy outcome
    Meeting Abstract

    Imber, B. S.; Silverman, E. A.; Leithner, D.; Hubbeling, H.; Shah, G. L.; Fregonese, B.; Sanin, B. W.; Tomas, A. A.; Parascondola, A.; Saldia, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • A multicenter phase II, double-blind, placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 trial
    Journal Article

    Bashir, Q.; Nishihori, T.; Pasquini, M. C.; Martens, M. J.; Wu, J.; Alsina, M.; Anasetti, C.; Brunstein, C.; Dawson, P.; Efebera, Y.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients
    Journal Article

    Nguyen, C. L.; Markey, K. A.; Miltiadous, O.; Dai, A.; Waters, N.; Sadeghi, K.; Fei, T.; Shouval, R.; Taylor, B. P.; Liao, C.; more...
    Cell (2023)

    Fulltext@MSK | Save
  • EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation
    Journal Article

    Sanchez-Escamilla, M.; Flynn, J.; Devlin, S.; Maloy, M.; Fatmi, S. A.; Tomas, A. A.; Escribano-Serrat, S.; Ponce, D.; Sauter, C. S.; Giralt, S. A.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save